

# AUSTRALIAN PRODUCT INFORMATION - FLUZONE™ INFLUENZA VIRUS HAEMAGGLUTININ

## 1 NAME OF THE MEDICINE

Inactivated Trivalent Influenza Vaccine, Split Virion (Influenza virus haemagglutinin)

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Fluzone for intramuscular injection is an inactivated influenza virus vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octoxinol-9 (Triton® X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution. Antigens from the three strains included in the vaccine are produced separately and then combined to make the trivalent formulation.

It is formulated to contain the following three influenza strains\* recommended for the 2025 influenza season:

Active Substance	Quantity (per 0.5 mL dose)
A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Victoria/4897/2022, IVR-238)	15 micrograms HA**
A/Croatia/10136RV/2023 (H3N2)-like strain (A/Croatia/10136RV/2023, X-425A)	15 micrograms HA**
B/Austria/1359417/2021-like strain (B/Michigan/01/2021, wild type)	15 micrograms HA**

\* propagated in fertilised hens' eggs from healthy chicken flocks

\*\* haemagglutinin

Fluzone contains 45 micrograms (µg) hemagglutinin (HA) per 0.5 mL dose, in the recommended ratio of 15 µg HA per strain.

The type and amount of viral antigens contained in Fluzone conform to the annual requirements of the Australian Influenza Vaccine Committee (AIVC) and the World Health Organization (WHO) recommendations for the season.

Neither antibiotics nor preservative are used during manufacture.

Fluzone is presented in prefilled syringes that are not made with natural rubber latex.

### 3 PHARMACEUTICAL FORM

Sterile aqueous suspension for injection.

Fluzone suspension for injection is clear and slightly opalescent in colour.

### 4 CLINICAL PARTICULARS

#### 4.1 THERAPEUTIC INDICATIONS

Fluzone is indicated for active immunisation of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone is indicated for use in adults and children 6 months and older.

Fluzone should be given in accordance with the national recommendation as per the current Immunisation Handbook.

#### 4.2 DOSE AND METHOD OF ADMINISTRATION

Inspect Fluzone visually for particulate matter and/or discolouration prior to administration. If any of these defects or conditions exist, the vaccine should not be administered.

Before administering a dose of vaccine, shake the prefilled syringe.

The syringe is for single use only and must not be reused. Discard any remaining unused contents.

For needle size and length, refer to the national recommendations as per the current Immunisation Handbook.

Fluzone should not be mixed with any other vaccine in the same syringe or vial.

Administration should be carried out by the intramuscular route. The dose and schedule are as follows:

**Table 1 - Recommended influenza vaccine dosage per age**

Age	Vaccination Status	Dose	Schedule
6 months through 8 years	Not previously vaccinated with influenza vaccine or unknown vaccination history	Two 0.5 mL doses	Administer at least 4 weeks apart
	Previously vaccinated with influenza vaccine	One or two 0.5 mL doses <sup>a</sup>	If two doses, administer at least 4 weeks apart
9 years and older	-	One 0.5 mL dose	-

<sup>a</sup> Refer to the current Immunisation Handbook for the recommended doses of influenza vaccine for young children at different ages.

The preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle

if muscle mass is adequate) in persons  $\geq 12$  months through 35 months of age, or the deltoid muscle in persons  $>36$  months of age.

The vaccine should be administered into healthy well-developed muscle and should not be injected into the gluteal region where there may be a risk of local neural, vascular and tissue injury.

### **4.3 CONTRAINDICATIONS**

Fluzone should not be administered to anyone with a known systemic hypersensitivity reaction, such as anaphylaxis, after previous administration of any influenza vaccine or to any component of the vaccine (see Section 2 Qualitative and Quantitative Composition and Section 6.1 List of excipients).

### **4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE**

Do not administer intravenously.

#### **Hypersensitivity**

Prior to any vaccine injection, all known precautions should be taken to prevent hypersensitivity reactions. This includes a review of the individual's prior vaccination history with respect to possible hypersensitivity to the vaccine or similar vaccines.

As each dose may contain traces of formaldehyde and octoxinol-9 which are used during vaccine production, caution should be exercised when the vaccine is administered to individuals with hypersensitivity to either one of these products.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following administration of the vaccine especially for individuals who have a known allergy to egg protein.

#### **Febrile or Acute Disease**

Vaccination should be postponed in case of moderate or severe acute or febrile disease with or without fever but a mild disease with low-grade fever is usually not a reason to postpone vaccination.

#### **Neurological disorders**

Patients with a history of Guillain-Barré Syndrome (GBS) with an onset related in time to influenza vaccination may be at increased risk of again developing GBS, but whether vaccination specifically might increase the risk for recurrence is unknown. Because patients with a history of GBS have an increased likelihood of again developing the syndrome, the chance of them coincidentally developing the syndrome following influenza vaccination may be higher than in individuals with no history of GBS. If GBS has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone should be based on careful consideration of the potential benefits and risks. Refer to the current Immunisation Handbook for further details.

## **Immunosuppressive treatments or conditions**

The immunogenicity of Fluzone may be reduced by immunosuppressive treatment or in individuals with immune deficiency syndromes. Vaccination of individuals with chronic immunodeficiencies is recommended even though the antibody response may be limited.

## **Protection**

Influenza virus is remarkably unpredictable in that significant antigenic changes may occur from time to time. It is known that influenza vaccines, as now constituted, are not effective against all possible strains of influenza virus. Protection is limited to those strains of virus from which the vaccine is prepared or to closely related strains.

As with any vaccine, vaccination with Fluzone may not protect 100% of susceptible individuals.

## **Bleeding disorder**

Because any intramuscular injection can cause an injection-site haematoma in individuals with any bleeding disorder, such as haemophilia or thrombocytopenia, or in individuals on anticoagulant therapy, intramuscular injections with Fluzone should not be administered to such individuals unless the potential benefits outweigh the risk of administration. If the decision is made to administer any product by intramuscular injection to such individuals, it should be given with caution, with steps taken to avoid the risk of haematoma formation following injection.

## **Syncope**

Syncope (fainting) has been reported following vaccination with Fluzone. Procedures should be in place to prevent falling injury and manage syncopal reactions.

## **Use in the elderly**

Safety and immunogenicity of Fluzone were evaluated in adults 65 years of age and older (See Section 5.1 Pharmacodynamic Properties, Clinical Trials). Antibody responses to Fluzone are lower in individuals  $\geq 65$  years of age than in younger adults.

Adults aged  $\geq 65$  years are strongly recommended to receive either high-dose or adjuvanted influenza vaccine every year. Refer to the current Immunisation Handbook.

## **Paediatric use**

Safety and effectiveness of Fluzone in children below the age of 6 months have not been established. Children in Study GRC88 aged between 6 and  $< 12$  months were required to be born at full term of pregnancy ( $\geq 37$  weeks) and/or with a birth weight  $\geq 2.5$  kg.

Preterm infants ( $< 37$  weeks gestation) are strongly recommended to receive influenza vaccine each year, starting at  $\geq 6$  months of age. Refer to the current Immunisation Handbook.

## **Effects on laboratory tests**

Interference of Fluzone with laboratory and/or diagnostic tests has not been studied.

Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, hepatitis C, and especially HTLV1 have been observed. An appropriate Western Blot test should be used to confirm or disprove the results of the ELISA test. The transient false-positive reactions could be due to a non-specific IgM response induced by the vaccine.

## **4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**

Fluzone should not be mixed with any other vaccine in the same syringe or vial.

Adult target groups for influenza and pneumococcal polysaccharide vaccination overlap considerably. Clinical studies show that influenza vaccine may be administered with pneumococcal vaccine using separate syringes at different sites.

No studies regarding the simultaneous administration of inactivated influenza vaccine and other childhood vaccines have been conducted. According to ACIP, inactivated vaccines usually do not interfere with the immune response to other inactivated or live vaccines and children at high risk for influenza-related complications, including those aged 6-23 months, can receive influenza vaccine at the same time they receive other routine vaccinations.

If Fluzone is to be given at the same time as another injectable vaccine(s), the vaccine(s) should always be administered at different injection sites. Refer to the current Immunisation Handbook for further details.

Although inhibition of hepatic clearance of phenytoin, theophylline and warfarin has been reported after influenza vaccination, subsequent studies have not shown any evidence of undesirable effects related to this phenomenon.

If the vaccine is used in individuals deficient in producing antibodies due to immunosuppressive therapy, the expected immune response may not be obtained.

## **4.6 FERTILITY, PREGNANCY AND LACTATION**

### **Effects on fertility**

Fluzone has not been evaluated for the possible effects on human fertility. A reproductive toxicity study in which female rabbits were administered a Fluzone QIV formulation, 24 and 10 days before insemination showed no effects on female fertility.

### **Use in pregnancy (Category A)**

Animal reproductive studies have not been conducted with Fluzone. A developmental and reproductive toxicity study has been performed in female rabbits at a dose approximately 20 times the human dose (on a mg/kg basis) and has revealed no evidence of impaired female

fertility or harm to the fetus due to Fluzone QIV formulation. There are, however, no adequate and well-controlled studies in pregnant women.

In the developmental and reproductive toxicity study, female rabbits were administered a Fluzone QIV formulation or control saline (each 0.5 mL/dose) by intramuscular injection 24 and 10 days before insemination, and on Days 6, 12, and 27 of gestation. The administration of a Fluzone QIV formulation did not result in systemic maternal toxicity (no adverse clinical signs and no change in body weight or food consumption). In addition, no adverse effects on pregnancy, parturition, lactation, or embryo-fetal or pre-weaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis noted in this study.

It is also not known whether Fluzone can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Data from studies involving large numbers of women (> 80,000) vaccinated during pregnancy with inactivated influenza vaccines do not indicate any adverse fetal and maternal outcomes attributable to the vaccine. Fluzone should be given to a pregnant woman following an assessment of the risks and benefits. Because of the known adverse consequences of influenza infection in pregnant women, health authorities recommend vaccination of pregnant women.

#### **Use in lactation**

It is not known whether Fluzone is excreted in human milk hence, caution should be used when administering vaccine to breastfeeding women.

### **4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

No studies on the effects on the ability to drive or use machines have been performed.

### **4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)**

#### **Clinical trials experience**

Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trial of another vaccine and may not reflect the rates observed in practice.

#### ***Children 6 Months through 8 Years of Age***

In a multi-centre study conducted in the US (FID07), children 6 months through 35 months of age received two 0.25 mL doses of Fluzone, and children 3 years through 8 years of age received two 0.5 mL doses of Fluzone, irrespective of previous influenza vaccination history. The two doses (year 2006-2007 formulation) were administered 26 to 30 days apart. The safety analysis set included 97 children 6 months through 35 months of age and 163 children 3 years through 8 years of age. Table 2 and Table 3 summarise solicited injection site reactions and systemic adverse events reported within 7 days post-vaccination via diary cards.

**Table 2 - Frequency of Solicited Injection Site Reactions and Systemic Adverse Events Within 7 Days After Vaccination with Fluzone, Children 6 Through 35 Months of Age**

	Dose 1 (N <sup>a</sup> =90-92) Percentage			Dose 2 (N <sup>a</sup> =86-87) Percentage		
	Any	Moderate <sup>b</sup>	Severe <sup>c</sup>	Any	Moderate <sup>b</sup>	Severe <sup>c</sup>
Injection-Site Tenderness	47.3	8.8	0.0	56.3	3.4	1.1
Injection-Site Erythema	29.3	0.0	0.0	32.2	1.1	0.0
Injection-Site Swelling	16.7	0.0	0.0	14.9	0.0	0.0
Injection-Site Induration	14.4	0.0	0.0	16.1	0.0	0.0
Injection-Site Ecchymosis	14.4	1.1	0.0	14.9	2.3	0.0
Fever <sup>d</sup>	11.0	4.4	0.0	10.3	3.4	1.1
Vomiting	6.6	1.1	0.0	8.1	5.8	0.0
Crying Abnormal	31.9	11.0	0.0	18.6	7.0	2.3
Drowsiness	26.4	1.1	0.0	26.7	4.7	0.0
Appetite Lost	23.1	8.8	0.0	19.8	5.8	1.2
Irritability	42.9	19.8	1.1	34.9	17.4	4.7

<sup>a</sup>N is the number of vaccinated subjects with available data for the events listed

<sup>b</sup> Moderate - Injection-site tenderness: cries and protests when injection site is touched; Injection-site erythema, Injection-site swelling, Injection-site induration, and Injection-site ecchymosis:  $\geq 2.5$  cm to  $< 5$  cm; Fever:  $> 101.3^{\circ}\text{F}$  ( $38.5^{\circ}\text{C}$ ) to  $\leq 103.1^{\circ}\text{F}$  ( $39.5^{\circ}\text{C}$ ); Vomiting: 2 to 5 episodes per 24 hours; Crying abnormal: 1 to 3 hours; Drowsiness: not interested in surroundings or did not wake up for a meal; Appetite lost: missed 1 or 2 feeds completely; Irritability: requiring increased attention

<sup>c</sup> Severe - Injection-site tenderness: cries when injected limb is moved or the movement of the injected limb is reduced; Injection-site erythema, Injection-site swelling, Injection-site induration, and Injection-site ecchymosis:  $\geq 5$  cm; Fever:  $> 103.1^{\circ}\text{F}$  ( $39.5^{\circ}\text{C}$ ); Vomiting:  $\geq 6$  episodes per 24 hours or requiring parenteral hydration; Crying abnormal:  $> 3$  hours; Drowsiness: sleeping most of the time or difficulty to wake up; Appetite lost: refuses  $\geq 3$  feeds or refuses most feeds; Irritability: inconsolable

<sup>d</sup> Fever - Any Fever indicates  $\geq 100.4^{\circ}\text{F}$  ( $38.0^{\circ}\text{C}$ ). The percentage of temperature measurements that were taken by rectal, axillary, or oral routes, or not recorded were 69.2%, 17.6%, 13.2%, and 0.0%, respectively for Dose 1; and 69.0%, 13.8%, 16.1%, and 1.1%, respectively for Dose 2

**Table 3 - Frequency of Solicited Injection Site Reactions and Systemic Adverse Events Within 7 Days After Vaccination with Fluzone, Children 3 Through 8 Years of Age**

	Dose 1 (N <sup>a</sup> =150-151) Percentage			Dose 2 (N <sup>a</sup> =144-145) Percentage		
	Any	Moderate <sup>b</sup>	Severe <sup>c</sup>	Any	Moderate <sup>b</sup>	Severe <sup>c</sup>
Injection-Site Pain	59.3	8.0	0.0	62.1	9.7	0.7
Injection-Site Erythema	27.8	3.3	0.7	27.6	2.1	0.7
Injection-Site Swelling	19.9	5.3	0.0	14.5	2.8	0.0
Injection-Site Induration	16.6	2.0	0.0	11.7	1.4	0.0
Injection-Site Ecchymosis	12.6	0.7	0.7	15.2	0.7	0.0
Injection-Site Pruritus	7.3	-	-	13.2	-	-
Fever <sup>d</sup>	11.9	2.6	2.0	9.7	1.4	1.4
Headache	16.7	2.0	0.7	11.8	1.4	1.4
Malaise	20.0	2.7	1.3	14.6	4.2	0.7
Myalgia	28.0	5.3	0.0	17.4	4.2	0.0

Dose 1 (N <sup>a</sup> =150-151) Percentage			Dose 2 (N <sup>a</sup> =144-145) Percentage		
Any	Moderate <sup>b</sup>	Severe <sup>c</sup>	Any	Moderate <sup>b</sup>	Severe <sup>c</sup>

<sup>a</sup>N is the number of vaccinated subjects with available data for the events listed

<sup>b</sup> Moderate - Injection-site pain: sufficiently discomforting to interfere with normal behavior or activities; Injection-site erythema, Injection-site swelling, Injection-site induration, and Injection-site ecchymosis:  $\geq 2.5$  cm to  $< 5$  cm; Fever:  $> 100.4^{\circ}\text{F}$  ( $38.0^{\circ}\text{C}$ ) to  $\leq 102.2^{\circ}\text{F}$  ( $39.0^{\circ}\text{C}$ ); Headache, Malaise, and Myalgia: interferes with daily activities

<sup>c</sup> Severe - Injection-site pain: incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism; Injection-site erythema, Injection-site swelling, Injection-site induration, and Injection-site ecchymosis:  $\geq 5$  cm; Fever:  $> 102.2^{\circ}\text{F}$  ( $39.0^{\circ}\text{C}$ ); Headache, Malaise, and Myalgia: prevents daily activities

<sup>d</sup> Fever - Any Fever indicates  $\geq 99.5^{\circ}\text{F}$  ( $37.5^{\circ}\text{C}$ ). The percentage of temperature measurements that were taken by oral or axillary routes, or not recorded were 93.4%, 6.6%, and 0.0%, respectively for Dose 1; and 93.1%, 6.2%, and 0.7%, respectively for Dose 2

"-" indicates information was not collected

The most frequently reported solicited injection site reactions within 7 days following dose 1 and dose 2 vaccination were tenderness (47% and 56%) and redness (29% and 32%) in children 6 months through 35 months; or pain (59% and 62%) and erythema (27% and 27%) in children 3 years through 8 years. The most frequently reported solicited systemic adverse events within 7 days following dose 1 and dose 2 vaccination were irritability (43% and 35%), crying abnormal (32% and 19%), and drowsiness (26% and 27%) in children 6 months through 35 months; or myalgia (28% and 17%), malaise (20% and 15%), and headache (17% and 12%) in children 3 years through 8 years.

During the period from the first vaccination through 6 months following the second vaccination, there were no serious adverse events considered to be caused by vaccination and no deaths reported in this study.

### ***Children 6 Months through 35 Months of Age***

Safety data collected in the GRC88 study conducted using a Quadrivalent Influenza Vaccine (QIV) formulation can support the 0.5-mL dose of the TIV in children 6 to 35 months. Removal of B/Yamagata strain from the Fluzone QIV is unlikely to impact the efficacy of A/H1N1, A/H3N2 and B/Victoria.

GRC88 was an observer-blind multi-centre study conducted in the US, including healthy children age between 6 and 35 months. Infants less than 12 months of age were of gestational age  $\geq 37$  weeks and/or birth weight  $\geq 2.5$  kg. Participants were randomly assigned to receive a Quadrivalent Influenza Vaccine dose of 0.25 mL (Group 1) or 0.5 mL (Group 2). For children requiring a second dose, the same dose was administered 4 weeks after the first. Participants who received at least one dose of study vaccine were included in the safety analysis set: Group 1 n = 949; Group 2 n = 992.

Table 4 summarises solicited injection-site and systemic adverse reactions reported within 7 days post-vaccination via diary cards for the 0.25 mL and 0.5 mL volumes of Fluzone Quadrivalent in children 6 months through 35 months of age.



**Table 4 - GRC88<sup>a</sup>: Percentage of Solicited Injection-site and Systemic Adverse Reactions Within 7 Days After Vaccination in Children 6 Months Through 35 Month of Age (Safety Analysis Set)<sup>b</sup>**

	Fluzone Quadrivalent 0.25 mL <sup>c</sup> (N <sup>d</sup> =949)		Fluzone Quadrivalent 0.5 mL <sup>c</sup> (N <sup>d</sup> =992)	
	Any (%)	Grade 3 <sup>e</sup> (%)	Any (%)	Grade 3 <sup>e</sup> (%)
<b>Injection-site adverse reactions</b>				
Tenderness	47.3	1.7	50.4	1.2
Redness	23.1	0.0	24.3	0.2
Swelling	12.9	0.1	14.7	0.0
<b>Systemic adverse reactions</b>				
Irritability	47.4	3.6	48.6	4.0
Abnormal Crying	33.3	3.1	34.1	2.6
Drowsiness	31.9	2.1	31.3	1.6
Loss of Appetite	27.3	1.4	28.3	2.2
Fever ( $\geq 100.4^{\circ}\text{F}$ ) <sup>f</sup>	11.3	0.6	12.2	1.2
Vomiting	10.0	0.4	10.2	0.5

<sup>a</sup> NCT02915302

<sup>b</sup> The safety analysis set includes all persons who received at least one dose of Fluzone

<sup>c</sup> Participants received 1 or 2 doses according to ACIP recommendations

<sup>d</sup> N is the number of participants in the safety analysis set

<sup>e</sup> Grade 3 - Injection-site tenderness: Cries when injected limb is moved, or the movement of the injected limb is reduced; Injection-site redness, Injection-site swelling:  $\geq 50$  mm; Irritability: inconsolable; Abnormal Crying:  $> 3$  hours; Drowsiness: sleeping most of the time or difficult to wake up; Loss of Appetite: refuses  $\geq 3$  feeds/meals or refuses most feeds/meals; Fever:  $> 103.1^{\circ}\text{F}$ ; Vomiting:  $\geq 6$  episodes per 24 hours or requiring parenteral hydration

<sup>f</sup> Fever measured by any route

The difference in fever rate (Group 2 minus Group 1) was 0.84% (95% CI: -2.13%; 3.80%), meeting the prespecified non-inferiority criterion (upper limit of the 2-sided 95% CI of the difference in fever rates  $< 5\%$ ). Participants were monitored for unsolicited adverse events and SAEs during the 28 days following vaccination. Unsolicited non-serious adverse events were reported in 417 (44%) participants in Group 1 and 394 (40%) participants in Group 2. The most commonly reported unsolicited non-serious adverse events in both groups were cough and rhinorrhoea. Ten SAEs were reported during the 28-day follow-up period: 5 (0.5%) in Group 1 and 5 (0.5%) in Group 2.

## Adults

Adults 18 through 64 years of age received Fluzone (year 2008-2009 formulation) in a multi-centre trial conducted in the US (FID31). The safety analysis set included 1421 Fluzone recipients. Table 5 summarises solicited injection-site reactions and systemic adverse events reported within 7 days post-vaccination via diary cards.

**Table 5: Frequency of Solicited Injection-Site Reactions and Systemic Adverse Events Within 7 Days After Vaccination with Fluzone, Adults 18 Through 64 Years of Age**

	(N <sup>a</sup> =1392-1394) Percentage		
	Any	Grade 2 <sup>b</sup>	Grade 3 <sup>c</sup>
Injection-Site Erythema	13.2	2.1	0.9
Injection-Site Induration	10.0	2.3	0.5
Injection-Site Swelling	8.4	2.1	0.9
Injection-Site Pain	53.7	5.8	0.8
Injection-Site Pruritus	9.3	0.4	0.0
Injection-Site Ecchymosis	6.2	1.1	0.4
Headache	30.3	6.5	1.6
Myalgia	30.8	5.5	1.4
Malaise	22.2	5.5	1.8
Shivering	6.2	1.1	0.6
Fever <sup>d</sup>	2.6	0.4	0.2

<sup>a</sup> N is the number of vaccinated subjects with available data for the events listed

<sup>b</sup> Grade 2 - Injection-site erythema, Injection-site induration, Injection-site swelling, and Injection-site ecchymosis: ≥2.5 cm to <5 cm; Injection-site pain and Injection-site pruritus: sufficiently discomforting to interfere with normal behaviour or activities; Fever: >100.4°F (38.0°C) to ≤102.2°F (39.0°C); Headache, Myalgia, Malaise, and Shivering: interferes with daily activities

<sup>c</sup> Grade 3 - Injection-site erythema, Injection-site induration, Injection-site swelling, and Injection-site ecchymosis: ≥5 cm; Injection-site pain: incapacitating, unable to perform usual activities; Injection-site pruritus: incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism; Fever: >102.2°F (39.0°C); Headache, Myalgia, Malaise, and Shivering: prevents daily activities

<sup>d</sup> Fever - Any Fever indicates ≥99.5°F (37.5°C). The percentage of temperature measurements that were taken by oral or axillary routes, or not recorded were 99.6%, 0.0%, and 0.4%, respectively

The most frequently reported solicited injection-site reaction was pain (54%); the most frequently reported solicited systemic adverse events were myalgia (31%), headache (30%), and malaise (22%).

Within 28 days and six months post-vaccination, a serious adverse event was reported by 5 (0.4%) and 20 (1.4%) Fluzone recipients, respectively. No serious adverse event was considered to be caused by vaccination. No deaths were reported during the 6 months post-vaccination.

### **Geriatric Adults**

Adults 65 years of age and older received Fluzone (year 2006-2007 formulation) in a multi-centre, double-blind trial conducted in the US (FIM05). The safety analysis set included 1260 Fluzone recipients.

Table 6 summarises solicited injection-site reactions and systemic adverse events reported within 7 days post-vaccination via diary cards. Onset was usually within the first 3 days after vaccination and a majority of the reactions resolved within 3 days.

**Table 6: Frequency of Solicited Injection-Site Reactions and Systemic Adverse Events Within 7 Days After Vaccination with Fluzone, Adults 65 Years of Age and Older**

	N <sup>a</sup> =1258-1260 Percentage		
	Any	Moderate <sup>b</sup>	Severe <sup>c</sup>
Injection-Site Pain	24.3	1.7	0.2
Injection-Site Erythema	10.8	0.8	0.6
Injection-Site Swelling	5.8	1.3	0.6
Myalgia	18.3	3.2	0.2
Malaise	14.0	3.7	0.6
Headache	14.4	2.5	0.3
Fever <sup>d</sup>	2.3	0.2	0.1

<sup>a</sup> N is the number of vaccinated subjects with available data for the events listed

<sup>b</sup> Moderate - Injection-site pain: sufficiently discomforting to interfere with normal behaviour or activities;

Injection-site erythema and Injection-site swelling:  $\geq 2.5$  cm to  $< 5$  cm; Fever:  $> 100.4^{\circ}\text{F}$  ( $38.0^{\circ}\text{C}$ ) to  $\leq 102.2^{\circ}\text{F}$  ( $39.0^{\circ}\text{C}$ ); Myalgia, Malaise, and Headache: interferes with daily activities

<sup>c</sup> Severe - Injection-site pain: incapacitating, unable to perform usual activities; Injection-site erythema and Injection-site swelling:  $\geq 5$  cm; Fever:  $> 102.2^{\circ}\text{F}$  ( $39.0^{\circ}\text{C}$ ); Myalgia, Malaise, and Headache: prevents daily activities

<sup>d</sup> Fever –Any Fever indicates  $\geq 99.5^{\circ}\text{F}$  ( $37.5^{\circ}\text{C}$ ). The percentage of temperature measurements that were taken by oral route or not recorded were 98.6% and 1.4%, respectively

The most frequently reported solicited injection-site reaction was pain (24%); the most frequently reported solicited systemic adverse events were myalgia (18%), headache (14%), and malaise (14%).

Within 6 months post-vaccination, 93 (7.4%) Fluzone recipients experienced a serious adverse event (N=1260). No deaths were reported within 28 days post-vaccination. A total of 7 deaths were reported during the period Day 29-180 post-vaccination: 7 (0.6%) among Fluzone recipients (N=1260). The majority of these participants had a medical history of cardiac, hepatic, neoplastic, renal, and/or respiratory diseases. No deaths were considered to be caused by vaccination.

### Adverse reactions from post-marketing surveillance

Based on spontaneous reporting, the following adverse events have been reported following commercial use of Fluzone. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Adverse events were included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to Fluzone.

- *Blood and Lymphatic System Disorders*: Thrombocytopenia, lymphadenopathy
- *Immune System Disorders*: Anaphylaxis, other allergic/hypersensitivity reactions (including urticaria, angioedema)
- *Eye disorders*: Ocular hyperemia
- *Nervous System Disorders*: Guillain-Barré syndrome (GBS), convulsions, febrile convulsions, myelitis (including encephalomyelitis and transverse myelitis), facial

palsy (Bell's palsy), optic neuritis/neuropathy, brachial neuritis, syncope (shortly after vaccination), dizziness, paresthesia

- *Vascular Disorders*: Vasculitis, vasodilation/flushing
- *Respiratory, Thoracic and Mediastinal Disorders*: Dyspnea, pharyngitis, rhinitis, cough, wheezing, throat tightness
- *Skin and Subcutaneous Tissue Disorders*: Stevens-Johnson syndrome
- *General Disorders and Administration Site Conditions*: Pruritus, asthenia/fatigue, pain in extremities, chest pain
- *Gastrointestinal Disorders*: Vomiting

## Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

## 4.9 OVERDOSE

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

# 5 PHARMACOLOGICAL PROPERTIES

## 5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Influenza vaccine, ATC code: J07BB

### Mechanism of action

Influenza illness and its complications follow infection with influenza viruses. Global surveillance of influenza identifies yearly antigenic variants. For example, since 1977, antigenic variants of influenza A (H1N1 and H3N2) viruses and influenza B viruses have been in global circulation. Specific levels of hemagglutination inhibition (HAI) antibody titre post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza virus infection. In some human studies, antibody titres  $\geq 1:40$  have been associated with protection from influenza illness in up to 50% of subjects.

Antibodies against one influenza virus type or subtype confer limited or no protection against another. Furthermore, antibodies to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virological basis for seasonal epidemics and the reason for the usual change of one or more strains in each year's influenza vaccine. Therefore, influenza vaccines are standardised to contain the hemagglutinins of influenza virus strains representing the influenza viruses likely to be circulating in the upcoming season.

## Clinical trials

### *Immunogenicity of Fluzone in Children 6 Months to 8 Years of Age*

In a multi-centre study conducted in the US (FID07), 68 children 6 months through 35 months of age given two 0.25 mL doses of Fluzone and 120 children 3 years through 8 years of age given two 0.5 mL doses of Fluzone were included in the per-protocol analysis set. The two doses (year 2006-2007 formulation) were administered 26 to 30 days apart. Females accounted for 42.6% of the participants in the 6 months through 35 months age group and 53.3% of the participants in the 3 years through 8 years age group. Most participants in the 6 months through 35 months and 3 years through 8 years age groups, respectively, were Caucasian (70.6% and 79.2%), followed by Hispanic (19.1% and 13.3%), and Black (7.4% and 4.2%).

The percentage of participants who received influenza vaccination during the previous influenza season was 54.4% for the 6 months through 35 months age group and 27.5% for the 3 years through 8 years age group. Table 7 shows seroconversion rates and the percentage of participants with an HI titre  $\geq 1:40$  pre-vaccination and one month following the second dose of Fluzone.

Blood samples were obtained before dose 1 and 28 days post-dose 2. The proportion of children 6 months through 35 months of age with HI titres  $\geq 1:40$  increased from 12% pre-vaccination to 93% post-vaccination against A/H1N1, from 29% pre-vaccination to 100% post-vaccination against A/H3N2, and from 1.5% pre-vaccination to 21% post-vaccination against type B.

The proportion of children 3 years through 8 years of age with HI titres  $\geq 1:40$  increased from 40% pre-vaccination to 99% post-vaccination against A/H1N1, from 80% pre-vaccination to 100% post-vaccination against A/H3N2, and from 3.3% pre-vaccination to 58% post-vaccination against type B.

Seroconversion was defined for paired samples with a pre-vaccination HI titre  $< 1:10$  and post-vaccination titre  $\geq 1:40$  or a minimum 4-fold increase for participants with a pre-vaccination titre  $\geq 1:10$ . For children 6 months through 35 months of age, seroconversion rates against A/H1N1, A/H3N2, and B were 88%, 91%, and 21%, respectively. For children 3 years through 8 years of age, seroconversion rates were 78%, 62%, and 53%, respectively.

**Table 7: Percentage (%) with Pre and Post-Vaccination HI Titers  $\geq 1:40$  and Seroconversion Following the Second Vaccine Injection with Fluzone<sup>a</sup> in Children 6 Months Through 35 Months and 3 Years Through 8 Years of Age**

Antigen	Age Group	Pre-Vaccination Titer $\geq 1:40$ % (95% CI)	Post-Vaccination <sup>b</sup> Titer $\geq 1:40$ % (95% CI)	Seroconversion <sup>c</sup> % (95% CI)
N=68 (6 to 35 months); N=120 (3 through 8 years)				
A (H1N1)	6 through 35 months	11.8 (5.2; 21.9)	92.6 (83.7; 97.6)	88.2 (78.1; 94.8)
	3 through 8 years	40.0 (31.2; 49.3)	99.2 (95.4; 100.0)	78.3 (69.9; 85.3)
A (H3N2)	6 through 35 months	29.4 (19.0; 41.7)	100.0 (94.7; 100.0)	91.2 (81.8; 96.7)
	3 through 8 years	80.0 (71.7; 86.7)	100.0 (97.0; 100.0)	61.7 (52.4; 70.4)

Antigen	Age Group	Pre-Vaccination Titer ≥1:40 % (95% CI)	Post-Vaccination <sup>b</sup> Titer ≥1:40 % (95% CI)	Seroconversion <sup>c</sup> % (95% CI)
N=68 (6 to 35 months); N=120 (3 through 8 years)				
<b>B</b>	6 through 35 months	1.5 (0.0; 7.9)	20.6 (11.7; 32.1)	20.6 (11.7; 32.1)
	3 through 8 years	3.3 (0.9; 8.3)	58.3 (49.0; 67.3)	53.3 (44.0; 62.5)

<sup>a</sup> Children received two doses of Fluzone administered 26 to 30 days apart, irrespective of previous influenza vaccination history

<sup>b</sup> Post-vaccination HI titres drawn at 28 days post-dose

<sup>c</sup> Seroconversion: Paired samples with pre-vaccination HI titre <1:10 and post-vaccination (28 days post-dose 2) titre ≥1:40 or a minimum 4-fold increase for participants with pre-vaccination titre ≥1:10

### ***Immunogenicity of a 0.5 mL Dose of Quadrivalent Influenza Vaccine (QIV) in Children 6 months to 35 months***

GRC88 (NCT02915302 see <http://clinicaltrials.gov>) was a randomised, observer-blind, multi-centre study including healthy children age between 6 and 35 months, randomly assigned to receive a Quadrivalent Influenza Vaccine dose of 0.25 mL (Group 1) or 0.5 mL (Group 2). For children requiring a second dose, the same dose was administered 4 weeks after the first. The per-protocol immunogenicity set included 715 participants in Group 1 and 745 in Group 2. Immunogenicity was assessed 28 – 35 days after the final vaccination. (See also Section 4.8 Adverse effects).

HI antibody GMTs following the 0.5 mL dose of Quadrivalent Influenza Vaccine were non-inferior to those following a 0.25 mL dose for all four strains, based on pre-specified criteria of lower limit of the 2-sided 95% CI of the ratio of GMTs (GMT0.5mL/GMT0.25mL) > 0.667

- A/H1N1 strain: GMT ratio = 1.42(95% CI: 1.16; 1.74).
- A/H3N2 GMT ratio: = 1.48 (95% CI: 1.21; 1.82).
- B Victoria lineage strain GMT ratio: = 1.33 (95% CI: 1.09; 1.62).
- B Yamagata lineage strain GMT ratio: = 1.41 (95% CI: 1.17; 1.70).

Seroconversion rates 28 days following final vaccination with a 0.5 mL dose of Quadrivalent Influenza Vaccine were non-inferior to those following a 0.25 mL dose for all four strains, based on pre-specified criteria of lower limit of the 2-sided 95% CI of the difference in seroconversion rates > -10% (GMT0.5mL minus GMT0.25mL) > -10%).

- A/H1N1 strain: difference in SC rates = 4.6% (95% CI: 0.4%; 9.6%).
- A/H3N2 strain: difference in SC rates = 5.1 % (95% CI: 0.4%; 9.8%).
- B Victoria lineage strain: difference in SC rates = 1.3% (95% CI: -2.9%; 5.6%).
- For the B Yamagata lineage strain: difference in SC rates = 2.6% (95% CI: -1.4%; 6.5%).

### ***Immunogenicity of Fluzone in Adults***

Adults 18 through 64 years of age received Fluzone (year 2008-2009 formulation) in a multi-centre trial conducted in the US (FID31). For immunogenicity analyses, there were 1287

participants who received Fluzone in the per-protocol analysis set. There were fewer males (35.8%) than females. The mean age was 42.6 years (ranged from 18.2 through 65.0 years). Most participants were Caucasian (80.0%), followed by Hispanic (11.0%), and Black (6.3%). Table 8 shows seroconversion rates at 28 days following vaccination and the percentage of participants with an HI titre  $\geq 1:40$  prior to vaccination and 28 days following vaccination.

Blood samples were obtained pre-vaccination and 28 days post-vaccination. The proportion participants with HI titres  $\geq 1:40$  increased from 39% pre-vaccination to 92% post-vaccination against A/H1N1, from 34% pre-vaccination to 91% post-vaccination against A/H3N2, and from 41% pre-vaccination to 89% post-vaccination against type B. Seroconversion rates (defined in Section 15.1) against A/H1N1, A/H3N2, and B were 61%, 75%, and 54%, respectively.

**Table 8: Percentage (%) with Pre and Post-Vaccination HI Titres  $\geq 1:40$  and Seroconversion in Adult Fluzone Recipients 18 Through 64 Years of Age**

Antigen	Pre-Vaccination Titre $\geq 1:40$ % (95% CI) N <sup>c</sup> =1285-1286	Post-Vaccination <sup>a</sup> Titre $\geq 1:40$ % (95% CI) N <sup>c</sup> =1283-1285	Seroconversion <sup>b</sup> % (95% CI) N <sup>c</sup> =1283-1285
A (H1N1)	39.1 (36.4; 41.8)	91.7 (90.0; 93.1)	60.5 (57.7; 63.2)
A (H3N2)	33.6 (31.0; 36.2)	91.4 (89.8; 92.9)	74.8 (72.3; 77.1)
B	41.2 (38.5; 44.0)	89.3 (87.4; 90.9)	54.2 (51.4; 56.9)

<sup>a</sup> Post-vaccination HI titres drawn at 28 days post-dose

<sup>b</sup> Seroconversion: Paired samples with pre-vaccination HI titre  $< 1:10$  and post-vaccination (28 days post-dose) titre  $\geq 1:40$  or a minimum 4-fold increase for participants with pre-vaccination titre  $\geq 1:10$

<sup>c</sup> N is the number of vaccinated subjects with available data for the immunologic endpoint listed

### ***Immunogenicity of Fluzone in Adults $\geq 65$ Years of Age***

Adults 65 years of age and older received Fluzone (year 2006-2007 formulation) in a multi-centre trial conducted in the US (FIM05). For immunogenicity analyses, there were 1,275 participants who received Fluzone in the immunogenicity analysis set. Females accounted for 54.7% of participants. The mean age was 72.9 years (ranged from 65 through 94 years of age); 36% of participants were 75 years of age or older. Most participants were Caucasian (92.9%), followed by Hispanic (3.7%), and Black (2.7%). Table 9 shows seroconversion rates at 28 days following vaccination and the percentage of participants with an HI titre  $\geq 1:40$  prior to vaccination and 28 days following vaccination.

Blood samples were obtained pre-vaccination and 28 days post-vaccination. The proportion participants with HI titres  $\geq 1:40$  increased from 46% pre-vaccination to 77% post-vaccination against A/H1N1, from 69% pre-vaccination to 97% post-vaccination against A/H3N2, and from 27% pre-vaccination to 68% post-vaccination against type B. Seroconversion rates (defined in Section 15.1) against A/H1N1, A/H3N2, and B were 23%, 51%, and 30%, respectively.

**Table 9: Percentage (%) with Pre and Post-Vaccination HI Titres  $\geq 1:40$  and Seroconversion in Adult Fluzone Recipients 65 Years of Age and Older**

Antigen	Pre-Vaccination	Post-Vaccination <sup>a</sup>	Seroconversion <sup>b</sup>
	HI Titer $\geq 1:40$ % (95% CI) N <sup>c</sup> =1267-1268	Titer $\geq 1:40$ % (95% CI) N <sup>c</sup> =1252	% (95% CI) N <sup>c</sup> =1248-1249
A (H1N1)	45.9 (43.2; 48.7)	76.8 (74.3; 79.1)	23.1 (20.8; 25.6)
A (H3N2)	68.6 (66.0; 71.2)	96.5 (95.3; 97.4)	50.7 (47.9; 53.5)
B	27.3 (24.9; 29.9)	67.6 (64.9; 70.2)	29.9 (27.4; 32.6)

<sup>a</sup> Post-vaccination HI titres drawn at 28 days post-dose

<sup>b</sup> Seroconversion: Paired samples with pre-vaccination HI titre  $< 1:10$  and post-vaccination (28 days post-dose) titre  $\geq 1:40$  or a minimum 4-fold increase for participants with pre-vaccination titre  $\geq 1:10$

<sup>c</sup> N is the number of vaccinated subjects with available data for the immunologic endpoint listed.

### **Efficacy of Fluzone in Adults**

GRC70 was a randomised, double-blind, placebo-controlled study conducted in a single US center during the 2007-2008 influenza season. Participants received one dose of either Fluzone vaccine (N = 813), an active comparator (N = 814), or placebo (N = 325). The intent-to-treat analysis set included 1138 healthy adults who received Fluzone or placebo. Participants were 18 through 49 years of age (mean age was 23.3 years); 63.3% were female, 83.1% were Caucasian, and 16.9% were of other racial/ethnic groups. Cases of influenza were identified through active and passive surveillance and confirmed by cell culture and/or real-time polymerase chain reaction (PCR). Influenza-like illness was defined as an illness with at least 1 respiratory symptom (cough or nasal congestion) and at least 1 constitutional symptom (fever or feverishness, chills, or body aches). Vaccine efficacy of Fluzone against all influenza viral types and subtypes is presented in Table 10.

**Table 10 - Estimated Efficacy of Fluzone Vaccine Against Influenza in Adults Aged 18 through 49 Years during the 2007-2008 Influenza Season – Intent-to-Treat Analysis Set\***

Laboratory-Confirmed Symptomatic Influenza	Fluzone <sup>†</sup> (N=813) §			Placebo <sup>†</sup> (N=325) §			Fluzone vs. Placebo	
	n <sup>¶</sup>	Rate (%)#	(95% CI)	n <sup>¶</sup>	Rate (%)#	(95% CI)	Relative Risk (95% CI)	Percent Relative Reduction <sup>‡</sup> (95% CI)
Positive culture	21	2.6	(1.6; 3.9)	31	9.5	(6.6; 13.3)	0.27 (0.16; 0.46)	73 (54; 84)
Positive PCR	28	3.4	(2.3; 4.9)	35	10.8	(7.6; 14.7)	0.32 (0.20; 0.52)	68 (48; 80)
Positive culture, positive PCR, or both	28	3.4	(2.3; 4.9)	35	10.8	(7.6; 14.7)	0.32 (0.20; 0.52)	68 (48; 80)

\* The intent-to-treat analysis set includes all enrolled participants who were randomly assigned to receive Fluzone or placebo and vaccinated  
<sup>†</sup>Fluzone: 2007-2008 formulation containing A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 (Victoria lineage)

<sup>‡</sup>Placebo: 0.9% NaCl

§N is the number of participants randomly assigned to receive Fluzone or placebo

<sup>¶</sup>n is the number of participants satisfying the criteria listed in the first column

#Rate (%) = (n/N) \* 100

<sup>‡</sup>Relative reduction in vaccine efficacy was defined as (1 - relative risk) x 100



## **5.2 PHARMACOKINETIC PROPERTIES**

No pharmacokinetic studies have been performed.

## **5.3 PRECLINICAL SAFETY DATA**

Fluzone has not been evaluated in non-clinical studies.

### **Genotoxicity**

Fluzone has not been evaluated for genotoxic potential.

### **Carcinogenicity**

Fluzone has not been evaluated for carcinogenic potential.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 LIST OF EXCIPIENTS**

Buffer Solution:

- Sodium chloride
- Dibasic sodium phosphate
- Monobasic sodium phosphate
- Water for injections

Fluzone may also contain traces of octoxinol-9 ( $\leq 250\mu\text{g}$ ), formaldehyde ( $\leq 100\ \mu\text{g}$ ) and ovalbumin ( $\leq 1\ \mu\text{g}$ ).

### **6.2 INCOMPATIBILITIES**

Fluzone should not be mixed with any other vaccine in the same syringe or vial.

### **6.3 SHELF LIFE**

12 months when stored at 2°C to 8°C.

### **6.4 SPECIAL PRECAUTIONS FOR STORAGE**

Store at 2°C to 8°C (Refrigerate, Do not freeze). Discard if vaccine has been frozen.

### **6.5 NATURE AND CONTENTS OF CONTAINER**

Prefilled syringe (clear syringe plunger rod), 0.5 mL with or without separate needle. Packs of 5 syringes.

Not all packs may be marketed.

The Fluzone presentation is not made with natural rubber latex.

## **6.6 SPECIAL PRECAUTIONS FOR DISPOSAL**

After use, any remaining vaccine and container must be disposed of safely, according to locally acceptable procedures.

## **6.7 PHYSIOCHEMICAL PROPERTIES**

Not applicable for vaccines.

## **7 MEDICINE SCHEDULE (POISONS STANDARD)**

S4 Prescription Only Medicine

## **8 SPONSOR**

**sanofi-aventis australia Pty Ltd**

12-24 Talavera Road

Macquarie Park NSW 2113

Australia

Freecall: 1800 818 806

Email: medinfo.australia@sanofi.com

## **9 DATE OF FIRST APPROVAL**

09 May 2025

## **10 DATE OF REVISION**

### **SUMMARY TABLE OF CHANGES**

<b>Section Changed</b>	<b>Summary of new information</b>